SOURCE: AirWare Labs

AirWare Labs

February 11, 2014 08:10 ET

AirWare Labs Enters Licensing Agreement With Breathe Active, LLC

AIR™ ALLERGY, AIR ESSENTIALS™ SLEEP/SNORE and HEADACHE Products to Be Licensed and Featured in a $2 Million National Television Media Campaign

SCOTTSDALE, AZ--(Marketwired - Feb 11, 2014) - AirWare Labs Corp. (OTCQB: AIRW) today announced a licensing agreement with Breathe Active, LLC for its AIR™ ALLERGY, AIR ESSENTIALS™ SLEEP/SNORE and AIR ESSENTIALS™ HEADACHE medical devices. Under the terms of the agreement, Breathe Active will offer these products to the public through a $2 million national television media campaign powered by Harvest Direct, a leading authority in direct response marketing and retail distribution.

Beginning this month, direct response commercials featuring Breathe Active Sleep/Snore and Allergy will air on cable channels including ESPN, MSNBC, CNBC, Hallmark Channel, MeTv, Game Show Network, FOX News, Biography and Lifetime Real Women. 

"This licensing agreement with Breathe Active further demonstrates that our products greatly improve the health and vitality of people suffering from a wide range of common conditions like allergies and headaches," said Jeffrey Rassás, President and CEO of AirWare Labs. "We are thrilled that Breathe Active and Harvest Direct are working to continue our mission to help people breathe -- and live -- better."

"We are very excited to help bring Breathe Active Sleep/Snore, Allergy and Headache to market," said Simon George, President of Harvest Direct. "Our internal tests and focus groups found these products to be extremely effective in treating conditions that millions of Americans struggle with on a daily basis. We know people are looking for safe, comfortable and natural relief from allergies, sleep disorders and headaches, and we are here to announce that relief has arrived."

In fact, Harvest Direct estimates the combined U.S. market for allergy, sleep and headache remedies is close to $200 billion annually.

"The Breathe Active licensing agreement puts AirWare Labs in a perfect position to capture a significant portion of this market," said Rassás.

AIR™ ALLERGY was selected last month as a 2014 Visionary Award Finalist for the VISION® Consumer Products Conference in Dallas, and in 2013 AirWare Labs announced a national rollout into 7,500 Walgreen's stores.

About AirWare Labs Corporation:

AirWare Labs Corp. [publicly traded as (OTCQB: AIRW)] provides patented and innovative technology solutions for consumer products that promote better health through breathing and enhanced wellbeing. AirWare Labs' products are marketed under the brand name of AIR®. AIR® products utilize an FDA approved medical grade silicone, molded as an intranasal Air Breathe dilator, to act as the delivery system. This AIR® microstructure enhances normal nasal airflow with every breath -- clinically proven to deliver up to 40% more oxygen. 

Some AIR® products are infused with essential oils with unique healing properties including antibacterial and therapeutic defense against airborne allergens, viruses and bacteria. AIR® Allergy and Travel products provide additional defense in the form of an integrated filter media from 3M to remove microscopic particles that carry viruses, allergens and bacteria. Other AIR® specialty products help provide and performance enhancements and relief from congestion, insomnia, headaches, nausea, and snoring. For more product information, please visit: or company information visit:

Forward-Looking Statement: The statements in this press release regarding any implied or perceived benefits from the release by AirWare Labs Corp. of its AIR ALLERGY™ product are forward-looking statements. Such statements involve risks and uncertainties, including, but not limited to, risks and effects of legal and administrative proceedings and governmental regulation, especially in a foreign country, future financial and operational results, competition, general economic conditions, and the ability to manage and continue growth.

Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual outcomes may vary materially from those indicated. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this news release include the introduction of new technology, market conditions and those set forth in reports or documents we file from time to time with the SEC. We undertake no obligation to revise or update such statements to reflect current events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Contact Information

  • Media Contact:
    Jennifer Breitegan

    Investor Relations:
    Jeffrey Rassas